NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aptah Bio

Aptah Bio

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://www.aptah-bio.com/

Last Round

Seed

Dec 24, 2024

Total Funding Raised

$18M

Company Overview

Aptah Bio is a biotechnology company that develops first-in-class RNA therapeutics targeting U1 snRNP dysfunction to slow tumor evolution, reduce cancer heterogeneity, and overcome adaptive resistance in glioblastoma and solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

RNA therapeuticsU1 snRNP modulationRNA WiCo platformpreclinical biotechfirst-in-class therapeuticsoncology therapeuticsglioblastomaneurodegenerative diseaseadaptive resistancedrug discovery platformpharma licensingAlzheimer's diseaseProgressive supranuclear palsyPSP

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aptah Bio Comparables

Compare Aptah Bio with similar companies based on industry and business-model similarity.

Aptah Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ceptur Therapeutics
84%
Skyhawk Therapeutics
72%
Inverna Therapeutics
72%

Aptah Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 24, 2024
Series AAug 14, 2023
AcceleratorAug 26, 2021

Key People

Founding team and executive leadership

Caio Leal

Chief Scientific Officer & Founder

Founding Team

Rafael M. Bottos

CEO

Executive Team

Aptah Bio Investors

Notable investors and investment history

Aptah Bio investors
InvestorRounds
Taihill VentureSeed
5Y CapitalSeed
K2VCSeed
UpHonest CapitalSeed
Financiadora de Estudos e ProjetosSeries A
Mission BioCapitalSeries A
VesperSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 13, 2025

    Monthly visitors increased 31% MoM.

  • Feb 26, 2025

    Monthly visitors increased 946% MoM, reaching 502.

Aptah Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aptah Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aptah Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range12
Year Founded2018
Last FundingDec 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.